The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (Bosulif) for the treatment of adult patients with chronic-phase, accelerated-phase, and blast-phase Philadelphia chromosome positive (Ph(+)) chronic myelogenous leukemia (CML) previ...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanaizi, Zahra, Unkrig, Christoph, Enzmann, Harald, Camarero, Jorge, Sancho-Lopez, Arantxa, Salmonson, Tomas, Gisselbrecht, Christian, Laane, Edward, Pignatti, Francesco
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2014
Subjects:
Regulatory Issues: EMA
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983815/
https://ncbi.nlm.nih.gov/pubmed/24668331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0294
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items